Am J Prev Med 42(6):563570 Mingrone G, Panunzi S, De Gaetano A et al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial
Sciuto AM, Strickland PT, Kennedy TP, Gurtner GH
First generation: short-acting Exenatide (Byetta) was the first GLP-1 receptor agonist approved by the FDA in 2005
Mounjaro doses Each Mounjaro dose contains the active ingredient tirzepatide
The clinical data on tirzepatide safety is robust -- over 9,800 participants across the SURMOUNT and SURPASS trial programs provide a clear picture of what to expect (Jastreboff et al., 2022)
Step 2: Pay the $65 consultation fee